he syndrome of non ST-segment elevation myocardial infarction (NSTEMI) accounts for much of the morbidity and mortality of cardiovascular disease. 1 It is well known that percutaneous coronary intervention (PCI) is a most effective treatment of acute NSTEMI for restoring blood flow within the culprit artery. 2 Recent studies indicate that a routine invasive approach for high-risk patients with NSTEMI yields improved outcomes compared with a conservative approach. 3,4 However, there are many patients who can not undergo PCI because of poor general health (eg, severe renal or liver disease, gastrointestinal bleeding, malignant neoplasm, chronic obstructive lung disease) or admission to a facility that cannot perform PCI. In addition, NSTEMI can occur after episodes of hypotension, severe sepsis or anemia in critical care patients with Circulation Journal Vol.72, September 2008 acute non-cardiac illness. 5, 6 In these situations appropriate conservative treatment is important.
T-wave inversion ≥0.2 mV in 2 contiguous leads).
We analyzed baseline demographic and clinical characteristics, relevant laboratory results, pharmacotherapy, mortality and morbidity during hospital stay. Killip class was evaluated at admission and the Thrombolysis In Myocardial Infarction (TIMI) risk score was calculated according to the guideline of Antman et al 7 for each patient. ECG and echocardiography were performed in all patients. Major adverse cardiac events (MACE) during a 1-month clinical follow-up were evaluated. All data were recorded on a standardized, electronic, web page-based case report form (http://www. kamir.or.kr).
Cardiogenic shock was defined as reduced blood pressure (systolic blood pressure <90 mmHg or decrease in mean arterial pressure >30 mmHg) and/or low urine output (<0.5 ml·kg -1 ·h -1 ), with a pulse rate >60 beats/min with or without evidence of organ congestion. 8 Baseline creatinine clearance was calculated using the Cockcroft -Gault formula taking into account age, sex and body weight. 9 Renal insufficiency was defined as creatinine clearance <60 ml/min.
Pharmacological Treatment
For all patients, the pharmacotherapy index based on the use of pharmacological treatment regimens according to the attending doctor's decision during hospital stay was assessed. Each patient received 1 point for each of the following guideline-recommended drugs: aspirin, clopidogrel, platelet glycoprotein IIb/IIIa inhibitor, low-molecularweight or unfractionated heparin, -blocker, angiotensinconverting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), statin, cilostazol, nicorandil and nitrate; the range of points was from 0 to 10. The drugs were administered intravenously for unfractionated heparin and glycoprotein IIb/IIIa inhibitor, subcutaneously for low-molecularweight heparin, and orally for the others.
Primary Endpoint
The primary endpoint was a composite of in-hospital death, complications, and MACE in the 1-month clinical follow-up. Death was defined as death from pump failure, mechanical complication (rupture of free wall, ventricular septal defect, mitral regurgitation etc), arrhythmia, sepsis, multi-organ failure, major bleeding, and non-cardiac origin. Cardiogenic shock, ventricular tachycardia and fibrillation (needed for anti-arrhythmic agent and/or defibrillation), atrioventricular blocker (needed for pacemaker), recurrent ischemia and MI, cerebrovascular accident, major bleeding, acute renal failure, multi-organ failure and sepsis were included as complications. MACE was defined as cardiac death, non-cardiac-death, MI, repeat PCI (target lesion or non-target lesion revascularization), and coronary artery bypass grafting.
Statistical Analysis
The SPSS for Windows, version 15.0 (Chicago, IL, USA) was used for all analyses. Continuous variables are presented as the mean value ± SD; comparisons were conducted by Student's t-test. Discrete variables are presented as percentages and relative frequencies; comparisons were made using chi-square statistics or Fisher's exact test as appropriate. Subgroups of high risk and low risk according to TIMI risk score, levels of high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-brain natriuretic peptide (NT-pro-BNP), and age were analyzed to minimize the selection bias. Logistic regression analysis was performed to identify the independent predictors of the primary endpoint. The 95% confidence interval for the relative risk was calculated using standard errors from the Kaplan-Meier curve. A p-value <0.05 was considered statistically significant.
Results

Study Population
Baseline characteristics and hemodynamics of the 847 patients who were followed for 1 month after discharge are shown in cardiogenic shock and 223 (27.3%) had a high Killip class (≥III).
Pharmacological Treatment
The mean pharmacotherapy index was 6.0±1.7. Most patients (32.6%) had 7 points (0 points: 0.9%; 1 point: 0.8%; 2 points: 2.0%; 3 points: 5.8%; 4 points: 7.7%; 5 points: 13.7%; 6 points: 21.8%; 7 points: 32.6%; 8 points: 12.6%; 9 points: 2.0%; 10 points: 0.0%). Patients with lower pharmacotherapy index values were more likely to have cardiogenic shock (5.3±2.0 with shock patients vs 6.1±1.6 with non-shock patients, p<0.001). There was no significant difference in the pharmacologic index according to the presence of hypertension, diabetes or hyperlipidemia and no significant correlation with age, TIMI risk score, Killip class, ejection fraction or laboratory results.
Primary Endpoints
Total in-hospital mortality and morbidity for the 1,124 patients was 15.8% and total 1-month MACE, including in-hospital mortality and morbidity, was 26.9%. Primary endpoints based on the drugs used during hospital stay are presented in Fig 1. In the univariate analysis, use of aspirin, clopidogrel, ACEI/ARB, -blocker, statins, nitrate, heparin, nicorandil, and cilostazol led to a significant reduction of inhospital death and complications (odds ratio=0.132, 0.392, 0.359, 0.384, 0.638, 0.644, 0.643, 0.634, 0.548, respectively, p<0.001, <0.001, <0.001, <0.001, 0.005, 0.009, 0.019, 0.021, 0.046 respectively; Table 2 ).
Primary Endpoints in Subgroup Analysis
The primary endpoints decreased with an increase of the pharmacotherapy index (p<0.001). In the subgroup analysis, the primary endpoints were significantly higher in the cardiogenic shock group than in the non-shock group (44.0% vs 24.9%, p<0.001). Higher pharmacologic index improved the clinical outcome in both the cardiogenic shock and nonshock group (p=0.003, <0.001, respectively) (Fig 2) .
All patients were categorized into 3 groups according to TIMI risk score. A total of 37.4% were classified as lowrisk (0-2 points), 39.1% as intermediate-risk (3-4 points), and 23.5% as high-risk (5-7 points). The primary endpoints of each subgroup are presented in Fig 3. The tendency for the primary endpoints to decrease with the increase of the pharmacotherapy index were observed in all 3 risk groups (Fig 3) (p=0.015, 0.003, <0.001, respectively).
The patients were classified by the levels of hs-CRP and NT-pro-BNP. The primary endpoints decreasing with the in- crease of pharmacotherapy index occurred in both the lower hs-CRP group (<0.875 mg/dl) and higher hs-CRP group (≥0.875 mg/dl) (p<0.001, 0.001, respectively) (Fig 4) , and similarly in both the lower NT-pro-BNP (<1,018 pg/ml) and higher NT-pro-BNP group (≥1,018 pg/ml) (p=0.015, 0.002, respectively) (Fig 5) . Subgroups were analyzed according to age. Overall, the primary endpoint was 35.5% in the elderly group (≥75 years, n=318) and 21.7% in the non-elderly group (<75 years, n=529). The primary endpoint decreased with the increase of pharmacotherapy index in both the elderly and non-elderly groups (0 points: 100%, 86%; 1 point: 100%, 80%; 2 points: 80%, 50%; 3 points: 54%, 48%; 4 points: 46%, 24%; 5 points: 37%, 25%; 6 points: 36%, 20%; 7 points: 28%, 15%; 8 points: 26%, 14%; 9 points: 20%, 8%; p=0.038, p< 0.001, respectively).
Multivariate Analysis of In-Hospital Mortality and Morbidity
In the multivariate regression analysis, independent predictors of in-hospital mortality and morbidity were high Killip score (≥II), low pharmacotherapy index (≤4 points), high levels of NT-pro-BNP (≥1,018 pg/ml), high levels of hs-CRP (≥0.875 mg/dl), and high TIMI risk score (≥5 points) (p<0.001, p<0.001, p=0.011, p=0.013, p=0.033, respectively) ( Table 3) .
Discussion
Acute coronary syndrome (ACS) is categorized into unstable angina, NSTEMI, and STEMI, 10 and the most effective treatment is revascularization using PCI. 11 The majority of recent studies are focused on invasive revascularization therapy for the management of ACS, 12-14 but in certain situations appropriate medical treatment is also important. Our data support the benefit of more aggressive pharmacological treatment in patients with NSTEMI who do not or cannot undergo PCI. Regardless of the risk profile, the proposed pharmacotherapy index was shown to be an independent predictor of short-term clinical outcomes. For every unit increase in the pharmacotherapy index, the rate of incidence of the primary endpoint decreased. Even though patients with cardiogenic shock and in poor general condition might receive less pharmacologic treatment because of contra- indications of each drug, in the present study the results were similar for the non-shock and low-risk groups, as well as for the shock and high-risk groups. Few clinical studies have investigated pharmacologic treatment for NSTEMI patients. Our results were comparable with those in previously reported clinical trials. 3, 4, 15 The Malopolska Registry of Acute Coronary Syndromes (MRACS) registry data demonstrated that more aggressive pharmacological treatment may improve clinical outcome in patients with NSTE ACSs treated conservatively. 15 The CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) registry data demonstrated that patients who presented with NSTEMI and did not receive guideline-recommended therapies had a higher mortality rate. 3 Similarly, Gulati et al have shown that compliance with recommended guidelines results in fewer adverse cardiac events, independent of the risk stratification model. 4 There are different points between the present study and previous trials. First, the previous trials (especially MRACS registry study) were conducted without on-site invasive facilities and the study populations were not transferred to other hospitals for invasive treatment. Therefore, there are many selection biases of enrollment in the study group. Patients who did not require PCI because of low disease severity or who could not be transferred to another hospital because of poor general condition were likely to be enrolled. Medication point
Lower NT-pro-BNP group (<1,018 pg/ml) p=0.015
Higher NT-pro-BNP group (>1,018 pg/ml) p=0.002 
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In contrast, our study was performed in high volume centers with facilities for PCI and on-site cardiac surgery, and thus the study population comprised patients who were not indicated for PCI. Therefore, the in-hospital mortality was higher than in previous trials and the selection bias was minimized. Second, our study used a 10-point scale. We incorporated recent advances in baseline medical therapy, such as the use of abciximab at the time of PCI, [16] [17] early use of clopidogrel, 18 intensive lipid-lowering therapy, 19, 20 the use of ACEI/ARB 21, 22 and nitrate, 23 and intensive glucose control, 24 all of which have been shown to improve outcomes in patients with acute NSTEMI. In addition, cilostazol, a phosphodiesterase inhibitor and an antiplatelet agent with a positive chronotropic effect, was used, with an impact on left ventricular volume and function in acute MI. 25 Also nicorandil, which has a myocardial protective effect during PCI in patients with ACS because of its ischemic preconditioning effect. 26 Third, previous trials evaluated only inhospital outcomes, whereas we evaluated not only in-hospital outcomes, but also MACE during a 1-month clinical follow-up. In our study, 55 (6.5%) patients experienced a MACE in the 1-month clinical follow-up. Fourth, our study evaluated the effect of pharmacologic treatment according to risk stratification. Higher TIMI risk score and levels of hs-CRP 27,28 and NT-pro-BNP 29, 30 are strong predictors of mortality in patients with ACS. In our study, patients were categorized into subgroups of high risk and low risk according to TIMI risk score and levels of hs-CRP and NTpro-BNP. Our results demonstrate that more aggressive pharmacologic treatment improved the clinical outcomes in both the high-risk and low-risk groups. Fifth, our study shows that the use of glycoprotein IIb/IIIa inhibitors did not improve the clinical outcomes, although the rate of usage was low, presumably because of the Japanese medical insurance system. 31 However, studies of coincidence result have been reported; for example, the GUSTO IV-ACS investigators 32 reported that a platelet glycoprotein IIb/IIIa inhibitor (Abciximab) has the potential to deteriorate the early prognosis of patients with NSTEMI who did not undergo early PCI. Therefore, more randomized controlled trials are necessary. Sixth, thrombolytic therapy was not performed in our study because it is thought to be ineffective for NSTEMI, according to many studies and the 2007 guidelines of ACC/AHA, 33 so the present patients with NSTEMI was not treated by thrombolytic agents even though their PCI had failed. Our proposed pharmacotherapy index can be interpreted as a predictor of favorable prognosis in patients with NSTEMI. On the other hand, patients with contraindications to the components of standard, guideline-recommended therapy (eg, with contraindications to antiplatelet drugs 34, 35 or to -blockers) 36 may have a higher risk of cardiovascular events in the short and long term. Recently, Peterson et al showed that adherence to guideline indices may be used as a surrogate marker in monitoring of hospitals' performance and for assessing overall quality of care. 37 
Study Limitations
First, our study was a multicenter prospective registry study and not a randomized and controlled study. Second, medical therapy during hospitalization was not randomized and the drugs used before hospitalization were not evaluated. It is likely that, in some patients, aggressive medical therapy was not used because of their good clinical status. Moreover, patients were not screened for other contraindications and indications for the use of each medication and the appropriateness of the dosage were not assessed. In particular, usage of ACEIs was not analyzed in the whole patient population, only in patients with left ventricular dysfunction or heart failure symptoms. 38, 39 Also, the route of administration of each drug was not unified, but that was unavoidable because that the marketed forms of the drugs was restricted. Third, the relative weight of each drug on outcome is probably not equal in the studied population. Usage of a diverse grading scale for each treatment could be justified. Finally, long-term clinical follow-up data were not available.
In conclusion, more intensive pharmacological treatment may improve short-term clinical outcome in NSETMI patients who are not indicated for PCI. Our findings support the need for more intensive pharmacological treatment of patients with NSTEMI.
